Gossamer Bio Lines Up Up to $250M Tied to Its Lung-Disease Drug’s FDA Filing

Gossamer Bio has secured a financing package worth up to $250 million, structured to release cash as its lead drug seralutinib advances through key regulatory milestones.

The private placement includes $150 million in committed capital: an initial closing of about $25 million via pre-funded warrants, and a further $125 million upon FDA acceptance of the drug’s New Drug Application (NDA). An additional $100 million could come in if post-approval warrants are exercised. Investors include EcoR1 Capital and RA Capital Management.

The drug

Seralutinib targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) — serious conditions in which high blood pressure in the lungs’ arteries strains the heart. Gossamer plans to submit its NDA in September 2026, and says the funds should sustain operations into 2028. The drug is partnered worldwide with Chiesi Farmaceutici.

Why it matters

“The committed funding structure aligns capital availability with key regulatory milestones,” Gossamer’s CEO said. For a clinical-stage biotech, milestone-linked financing is a way to raise substantial capital while limiting dilution until value-creating events — here, an FDA filing — actually land.